// App-Quantinova.ai

: High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Researchers

Presenter

  • Chong Chyn Chua

Principal Investigators

  • Anoop Kumar Enjeti

  • Devendra Hiwase

  • Paula Marlton

  • Ashish Bajel

  • Shuh Ying Tan

  • Edward S. Morris

  • Chun-Kei-Kris Ma

  • Carolyn Grove

  • Julian Cooney

  • Ashanka Beligaswatte

  • Rachel M Koldej

  • Stephen B Ting

  • Travis Perera

  • Amanda Johnston

  • John Reynolds

  • David Ritchie

  • Andrew H Wei

Medical Centers

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Department of Haematology, Calvary Mater Hospital, Waratah, Australia

  • St. Vincent's Hospital Melbourne, Fitzroy, Australia

  • Department of Haematology, Westmead Hospital, Sydney, Australia

  • Northern Hospital, Melbourne, Australia

  • The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

  • Wellington Blood and Cancer Centre, Wellington, New Zealand

  • Department of Haematology, Flinders Medical Centre, Adelaide, Australia

  • Department of Haematology, Eastern Health and Monash University, Melbourne, Australia

  • Department of Medicine, The University of Melbourne, Parkville, Australia

  • ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, Australia

  • Department of Haematology, Sir Charles Gairdner Hospital & PathWest, Nedlands, Australia

  • Department of Haematology, Royal Adelaide Hospital, Adelaide, Australia

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

  • Princess Alexandra Hospital and the University of Queensland, Brisbane, Australia

  • Townsville Cancer Centre, Townsville, Australia

  • Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, Australia

  • Department of Haematology, Fiona Stanley Hospital, Perth, Australia

Locations

  • Australia

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Myeloid neoplasms

  • Lymphomas

Biomarkers

  • Nucleophosmin 1

Drug/Treatment

  • Midostaurin

  • Cytarabine liposomal

  • Venetoclax

Outcome

  • N/A

Study Design

  • Safety

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved